News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Guidance
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G/A for Passage Bio, Inc. (PASG), indicating they no longer hold any beneficial ownership in the company. The filing shows 0 shares beneficially owned and 0% of outstanding common stock, with no …
This article first appeared on GuruFocus. Core Earnings to Shareholders: $34 million in Q2 2026, up from $25 million in Q1 2026. Net Income to Shareholders: $87 million, benefiting from favorable interest rate movements and strong equity markets. Annualized Core ROE: 13.6% for Q2, …
This article first appeared on GuruFocus. Core Earnings to Shareholders: $34 million in Q2 2026, up from $25 million in Q1 2026. Net Income to Shareholders: $87 million, benefiting from favorable interest rate movements and strong equity markets. Annualized Core ROE: 13.6% for Q2, …
Saga Communications, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance and Operational Context Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …
This article announces the filing of a Form 8K by Saga Communications Inc. on August 13th. The brief notice highlights the document's availability and mentions Saga Communications Inc. (SGA) and its stock performance.
Sagimet Biosciences (SGMT) reported its Q2 2026 results, announcing a strategic pivot towards dermatology. The company plans to advance its lead FASN inhibitor, denifanstat, into a U.S. Phase 3 acne trial and progress TVB-3567, backed by $257.6 million in cash which is expected to …
* Sagimet Biosciences press release [https://seekingalpha.com/pr/20614354-sagimet-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate] (SGMT [https://seekingalpha.com/symbol/SGMT]): Q2 GAAP EPS of -$0.26 in-line. * Cash, cash equivalents and marketable securities of $257.6 million as of June 30, 2026, expected to fund current operations through 2028, including through data readout of denifanstat Phase 3 …
Passage Bio (NASDAQ: PASG) reported stronger-than-expected Q2 results, with EPS of $(2.44), surpassing analyst estimates of $(3.47) by 29.68%. This performance also marked a 17.57% year-over-year improvement in losses compared to the previous year's $(2.96) per share deficit. The earnings beat suggests better cost …
Passage Bio reported a Q2 net loss of $7.82 million, a 16.67% improvement from the previous year, with an operating loss of $8.27 million. Despite reduced R&D expenses, general and administrative costs rose. The company is winding down gene-therapy programs, terminating key contracts, and …
Search by ticker symbol or company name and select a result to open its chart.